Evolution of the prostate cancer genome towards resistance

Abstract

The clinical behavior of prostate cancer is highly heterogeneous, with most patients diagnosed with localized disease that successfully responds to surgery or radiotherapy or that can be followed by active surveillance. However, a fraction of men will relapse after initial treatment and eventually progress to an aggressive resistant form with metastasis spreading and high mortality, a state referred to as castration resistant prostate cancer (CRPC). The technological advances in next generation sequencing have enabled the deep genomic and epigenomic characterization of both the hormone naïve and CRPC states, leading to the definition of molecular subclasses of prostate cancer that could inform the clinicians on therapeutic strategies. These studies also shed light on the mechanisms driving resistance to therapy. CRPCs adapt to androgen receptor (AR) signaling impairment - which follows first-line therapies as androgen deprivation or AR targeting - by restoring the nuclear receptor signaling by means of multiple mechanisms. Alternatively, tumor cells might become resistant to targeted therapies by exploiting lineage plasticity and activating alternative pathways. This review will discuss the main mechanisms leading to the emergence of resistance to therapy in prostate cancer patients in the context of genomic and molecular features of CRPC and on their causal role in the development of resistance.

Keywords

Prostate cancer / cancer evolution / resistance mechanisms / androgen receptor / metastases / castration resistant prostate cancer / genomics / epigenetics

References

[1] SiegelRL,JemalA.Cancer statistics, 2018..CA Cancer J Clin2018;68:7-30

[2] HugginsC.Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate..CA Cancer J Clin1972;22:232-40

[3] HugginsML.A new society for x-ray and electron diffraction research workers..Science1941;93:489-90

[4] BarrieSE,GoddardPM,DowsettM.Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase)..J Steroid Biochem Mol Biol1994;50:267-73

[5] ChanFC,BarrieSE,RowlandsMG.3- and 4-pyridylalkyl adamantanecarboxylates: inhibitors of human cytochrome P450(17 alpha) (17 alpha-hydroxylase/C17,20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer..J Med Chem1996;39:3319-23

[6] PotterGA,JarmanM.Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer..J Med Chem1995;38:2463-71

[7] TranC,CleggNJ,WatsonPA.Development of a second-generation antiandrogen for treatment of advanced prostate cancer..Science2009;324:787-90 PMCID:PMC2981508

[8] RubinMA.The genomics of prostate cancer: a historic perspective..Cold Spring Harb Perspect Med2018;

[9] Cancer Genome Atlas Research NetworkThe molecular taxonomy of primary prostate cancer..Cell2015;163:1011-25 PMCID:PMC4695400

[10] RubinMA,DemichelisF.Genomic correlates to the newly proposed grading prognostic groups for prostate cancer..Eur Urol2016;69:557-60

[11] BarbieriCE,LawrenceMS,BlattnerM.Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer..Nat Genet2012;44:685-9 PMCID:PMC3673022

[12] GandelliniP,RancatiT,DoldiV.Core biopsies from prostate cancer patients in active surveillance protocols harbor PTEN and MYC alterations..European Urology Oncology. Forthcoming2019;

[13] CamachoN,EdwardsS,MatthewsL.Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data..PLoS Genet2017;13:e1007001 PMCID:PMC5628936

[14] HieronymusH,GopalanA,ChangMT.Copy number alteration burden predicts prostate cancer relapse..Proc Natl Acad Sci U S A2014;111:11139-44 PMCID:PMC4121784

[15] BacaSC,LawrenceMS,RomanelA.Punctuated evolution of prostate cancer genomes..Cell2013;153:666-77 PMCID:PMC3690918

[16] FraserM,YamaguchiTN,LivingstoneJ.Genomic hallmarks of localized, non-indolent prostate cancer..Nature2017;541:359-64

[17] JaratlerdsiriW,PetersenDC,CroucherPI.Next generation mapping reveals novel large genomic rearrangements in prostate cancer..Oncotarget2017;8:23588-602 PMCID:PMC5410329

[18] QuigleyDA,ZhaoSG,AggarwalR.Genomic hallmarks and structural variation in metastatic prostate cancer..Cell2018;174:758-69.e9

[19] RobinsonD,WuYM,LonigroRJ.Integrative clinical genomics of advanced prostate cancer..Cell2015;161:1215-28 PMCID:PMC4484602

[20] RobinsonDR,LonigroRJ,CobainE.Integrative clinical genomics of metastatic cancer..Nature2017;548:297-303 PMCID:PMC5995337

[21] WedgeDC,MitchellT,MartincorenaI.Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets..Nat Genet2018;50:682-92 PMCID:PMC6372064

[22] ArmeniaJ,LiuD,KundraR.The long tail of oncogenic drivers in prostate cancer..Nat Genet2018;50:645-51 PMCID:PMC6107367

[23] GrassoCS,RobinsonDR,DhanasekaranSM.The mutational landscape of lethal castration-resistant prostate cancer..Nature2012;487:239-43 PMCID:PMC3396711

[24] KumarA,MacKenzieAP,LeeC.Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers..Proc Natl Acad Sci U S A2011;108:17087-92 PMCID:PMC3193229

[25] WatsonPA,SawyersCL.Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer..Nat Rev Cancer2015;15:701-11 PMCID:PMC4771416

[26] VisakorpiT,KoivistoP,KeinanenR.In vivo amplification of the androgen receptor gene and progression of human prostate cancer..Nat Genet1995;9:401-6

[27] MenonR,RuenauverK,PeiferM.Somatic copy number alterations by whole-exome sequencing implicates YWHAZ and PTK2 in castration-resistant prostate cancer..J Pathol2013;231:505-16

[28] RobinsonD,WuYM,LonigroRJ.Integrative clinical genomics of advanced prostate cancer..Cell2015;161:1215-28 PMCID:PMC4484602

[29] LinjaMJ,SaramakiOR,VessellaRL.Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer..Cancer Res2001;61:3550-5

[30] PalmbergC,KakkolaL,KallioniemiOP.Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer..J Urol2000;164:1992-5

[31] WalteringKK,SahuB,LinjaMJ.Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens..Cancer Res2009;69:8141-9

[32] ChenCD,TranC,ChenR.Molecular determinants of resistance to antiandrogen therapy..Nat Med2004;10:33-9

[33] ViswanathanSR,HoffAM,Carrot-ZhangJ.Structural alterations driving castration-resistant prostate cancer revealed by linked-read genome sequencing..Cell2018;174:433-47.e19 PMCID:PMC6046279

[34] TakedaDY,SeoJH,O’ConnorE.A somatically acquired enhancer of the androgen receptor is a noncoding driver in advanced prostate cancer..Cell2018;174:422-32.e13 PMCID:PMC6046260

[35] BeltranH,FramptonGM,DowningSR.Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity..European urology2013;63:920-6 PMCID:PMC3615043

[36] TaplinME,ShusterTD,SpoonerAE.Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer..N Engl J Med1995;332:1393-8

[37] AzadAA,WyattAW,Le BihanS.Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer..Clin Cancer Res2015;21:2315-24

[38] ConteducaV,SharabianiMTA,Fernandez-PerezMP.Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study..Ann Oncol2017;28:1508-16 PMCID:PMC5834043

[39] RomanelA,ConteducaV,CasiraghiN.Plasma AR and abiraterone-resistant prostate cancer..Sci Transl Med2015;7:312re10 PMCID:PMC6112410

[40] WyattAW,VolikSV,BejaK.Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer..JAMA Oncol2016;2:1598-606 PMCID:PMC5097690

[41] CarreiraS,GoodallJ,FerraldeschiR.Tumor clone dynamics in lethal prostate cancer..Sci Transl Med2014;6:254ra125 PMCID:PMC4422178

[42] JosephJD,QianJ,ShaoG.A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509..Cancer Discov2013;3:1020-9

[43] VeldscholteJ,KuiperGG,BerrevoetsC.A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens..Biochem Biophys Res Commun1990;173:534-40

[44] BalbasMD,HosfieldDJ,AroraVK.Overcoming mutation-based resistance to antiandrogens with rational drug design..Elife2013;2:e00499 PMCID:PMC3622181

[45] ChenEJ,GaoS,VoznesenskyO.Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors..Clin Cancer Res2015;21:1273-80 PMCID:PMC4359958

[46] ZhaoXY,KrishnanAV,NavoneNM.Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor..Nat Med2000;6:703-6

[47] TanJ,HamilKG,ZangDY.Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells..Mol Endocrinol1997;11:450-9

[48] DehmSM,HeemersHV,TindallDJ.Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance..Cancer Res2008;68:5469-77 PMCID:PMC2663383

[49] HuR,WeiS,VeltriRW.Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer..Cancer Res2009;69:16-22 PMCID:PMC2614301

[50] LuJ,NacusiLP,SchmidtLJ.The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells..J Urol2015;193:690-8 PMCID:PMC4411637

[51] ChanSC,LiY,MiaoL.Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies..Nucleic Acids Res2015;43:5880-97 PMCID:PMC4499120

[52] GuoZ,SunF,LinnDE.A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth..Cancer Res2009;69:2305-13 PMCID:PMC2672822

[53] LiY,FanD,TewfikAH.Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression..Cancer Res2011;71:2108-17 PMCID:PMC3059379

[54] LiY,OsethLA,VessellaRL.AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression..Oncogene2012;31:4759-67 PMCID:PMC3337879

[55] HenzlerC,YangR,HoY.Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer..Nat Commun2016;7:13668 PMCID:PMC5141345

[56] LiuLL,SunS,MostaghelE.Mechanisms of the androgen receptor splicing in prostate cancer cells..Oncogene2014;33:3140-50 PMCID:PMC4553036

[57] HornbergE,CrnalicS,StattinP.Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival..PLoS One2011;6:e19059 PMCID:PMC3084247

[58] MiyamotoDT,WittnerBS,ZhuH.RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance..Science2015;349:1351-6 PMCID:PMC4872391

[59] AntonarakisES,WangH,NakazawaM.AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer..N Engl J Med2014;371:1028-38

[60] EfstathiouE,WenS,KarlouM.Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer..Eur Urol2015;67:53-60 PMCID:PMC4247811

[61] AntonarakisES,LuberB,ChenY.Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide..J Clin Oncol2017;35:2149-56 PMCID:PMC5493048

[62] Del ReM,CrucittaS,RofiE.The Detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients..Eur Urol2017;71:680-7

[63] ScherHI,SchreiberNA,GrafRP.Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer..JAMA Oncol2016;2:1441-9 PMCID:PMC5206761

[64] ScherHI,SchreiberNA,WinquistE.Assessment of the validity of nuclear-localized androgen receptor splice variant 7 in circulating tumor cells as a predictive biomarker for castration-resistant prostate cancer..JAMA Oncol2018;4:1179-86 PMCID:PMC6139066

[65] ToSQ,FettkeHC,DocantoMM.Expression of androgen receptor splice variant 7 or 9 in whole blood does not predict response to androgen-axis-targeting agents in metastatic castration-resistant prostate cancer..Eur Urol2018;73:818-21

[66] LiY,BrandLJ,SilversteinKA.Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines..Cancer Res2013;73:483-9 PMCID:PMC3549016

[67] WatsonPA,BalbasMD,SocciND.Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor..Proc Natl Acad Sci U S A2010;107:16759-65 PMCID:PMC2947883

[68] CaiL,WangP,LiD.ZFX mediates non-canonical oncogenic functions of the androgen receptor splice variant 7 in castrate-resistant prostate cancer..Mol Cell2018;72:341-54.e6 PMCID:PMC6214474

[69] ChenZ,Thomas-AhnerJM,ZhaoP.Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13..Proc Natl Acad Sci U S A2018;115:6810-5 PMCID:PMC6042123

[70] MontgomeryRB,VessellaR,KalhornTF.Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth..Cancer Res2008;68:4447-54 PMCID:PMC2536685

[71] NishiyamaT,TakahashiK.The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer..Clin Cancer Res2004;10:7121-6

[72] ChangKH,KuriB,RoehrbornCG.A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer..Cell2013;154:1074-84 PMCID:PMC3931012

[73] KumarA,MorrisseyC,TrueLD.Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer..Nat Med2016;22:369-78 PMCID:PMC5045679

[74] TaylorBS,HieronymusH,XiaoY.Integrative genomic profiling of human prostate cancer..Cancer Cell2010;18:11-22 PMCID:PMC3198787

[75] HodgsonMC,ChengS,VerhoevenMC.The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists..J Biol Chem2005;280:6511-9

[76] LuNZ,BurnsteinKL,FullerPJ.International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors..Pharmacol Rev2006;58:782-97

[77] AroraVK,MuraliR,WongvipatJ.Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade..Cell2013;155:1309-22 PMCID:PMC3932525

[78] SahuB,PihlajamaaP,SinielnikovI.FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells..Cancer Res2013;73:1570-80

[79] GrindstadT,Al-SaadS,KiselevY.High progesterone receptor expression in prostate cancer is associated with clinical failure..PLoS One2015;10:e0116691 PMCID:PMC4344236

[80] AparicioA,MaitySN.Understanding the lethal variant of prostate cancer: power of examining extremes..Cancer Discov2011;1:466-8 PMCID:PMC4133693

[81] BeltranH,ParkK,MilowskyMI.Challenges in recognizing treatment-related neuroendocrine prostate cancer..J Clin Oncol2012;30:e386-9

[82] BeltranH,AparicioA,RickmanD.Aggressive variants of castration-resistant prostate cancer..Clin Cancer Res2014;20:2846-50 PMCID:PMC4040316

[83] WangHT,LiBG,ChangJW.Neuroendocrine prostate cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis..J Clin Oncol2014;32:3383-90

[84] AggarwalR,AlumkalJJ,FengFY.Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study..J Clin Oncol2018;36:2492-503 PMCID:PMC6366813

[85] BluemnEG,LucasJM,Hernandez-LopezS.Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling..Cancer Cell2017;32:474-89.e6 PMCID:PMC5750052

[86] ZouM,MitrofanovaA,HayatiS.Transdifferentiation as a mechanism of treatment resistance in a mouse model of castration-resistant prostate cancer..Cancer Discov2017;7:736-49 PMCID:PMC5501744

[87] BeltranH,MosqueraJM,PucaL.Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer..Nat Med2016;22:298-305 PMCID:PMC4777652

[88] KuSY,WangY,SeshadriM.Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance..Science2017;355:78-83 PMCID:PMC5367887

[89] MuP,BenelliM,HooverE.SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer..Science2017;355:84-8 PMCID:PMC5247742

[90] BishopJL,VahidS,KetolaK.The master neural transcription factor BRN2 is an androgen receptor-suppressed driver of neuroendocrine differentiation in prostate cancer..Cancer Discov2017;7:54-71

[91] ParkJW,SheuKM,BalanisNG.Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage..Science2018;362:91-5

[92] BeltranH,ParkK,SbonerA.Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets..Cancer Discovery2011;1:487-95 PMCID:PMC3290518

[93] DardenneE,BenelliM,BergerA.N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer..Cancer Cell2016;30:563-77 PMCID:PMC5540451

[94] WangW.Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases..Am J Surg Pathol2008;32:65-71

[95] JohnsonMH,AlshalalfaM,YousefiK.SPINK1 defines a molecular subtype of prostate cancer in men with more rapid progression in an at risk, natural history radical prostatectomy cohort..J Urol2016;196:1436-44

[96] LeinonenKA,BrackenH,TammelaTL.Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer..Clin Cancer Res2010;16:2845-51

[97] PanX,GongJ,YinX.The expression profile and prognostic value of SPINK1 in initially diagnosed bone metastatic prostate cancer..Prostate2016;76:823-33

[98] TomlinsSA,YuJ,MehraR.The role of SPINK1 in ETS rearrangement-negative prostate cancers..Cancer Cell2008;13:519-28 PMCID:PMC2732022

[99] ShuklaS,MurphyDA,RanL.Aberrant activation of a gastrointestinal transcriptional circuit in prostate cancer mediates castration resistance..Cancer Cell2017;32:792-806.e7 PMCID:PMC5728174

[100] ChesireDR,SauvageotJ,IsaacsWB.Detection and analysis of beta-catenin mutations in prostate cancer..Prostate2000;45:323-34

[101] VoellerHJ,GelmannEP.Beta-catenin mutations in human prostate cancer..Cancer Res1998;58:2520-3

[102] ChenG,PottiA,AprikianA.Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications..Cancer2004;101:1345-56

[103] ChesireDR,GageWR.In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis..Oncogene2002;21:2679-94

[104] TruicaCI,GelmannEP.Beta-catenin affects androgen receptor transcriptional activity and ligand specificity..Cancer Res2000;60:4709-13

[105] YangF,SharmaM,LongoDL.Linking beta-catenin to androgen-signaling pathway..J Biol Chem2002;277:11336-44

[106] NavaRodrigues D,RomanelA,MirandaS.RB1 heterogeneity in advanced metastatic castration-resistant prostate cancer..Clin Cancer Res2019;25:687-97

[107] HuaJT,GuoH,ChenS.Risk SNP-mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19..Cell2018;174:564-75.e18

[108] KhuranaE,ChakravartyD,RubinMA.Role of non-coding sequence variants in cancer..Nat Rev Genet2016;17:93-108

[109] GaoP,SipekyC,ZhangQ.Biology and clinical implications of the 19q13 aggressive prostate cancer susceptibility locus..Cell2018;174:576-89.e18 PMCID:PMC6091222

[110] RomanelA,StringaB,DalfovoD.Inherited determinants of early recurrent somatic mutations in prostate cancer..Nat Commun2017;8:48 PMCID:PMC5491529

[111] MateoJ,SandhuS,MossopH.DNA-repair defects and olaparib in metastatic prostate cancer..N Engl J Med2015;373:1697-708 PMCID:PMC5228595

[112] WuYM,LonigroRJ,ReimersMA.Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer..Cell2018;173:1770-82.e14 PMCID:PMC6084431